Biocon stock in focus after Pebrilzo FDA approval
Published on 11/20/2026 at 01:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory milestone and launch timing
- The FDA approved Pebrilzo, Biocon's pertuzumab biosimilar for HER2-positive breast cancer.
- A settlement with Genentech sets the earliest licensed U.S. launch for the third quarter of 2028.
- Biocon's portfolio now includes five U.S.-approved oncology biosimilars.
Biocon announced on November 16, 2026, that the U.S. Food and Drug Administration had approved Pebrilzo, its pertuzumab biosimilar for HER2-positive breast cancer. The company said the decision expands its U.S. oncology portfolio to five biosimilar therapies. The approval was reported in a Biocon press release.
Approval precedes U.S. launch
Pebrilzo is a monoclonal antibody biosimilar to Perjeta, used with other therapies in the treatment of HER2-positive breast cancer. Biocon said its global settlement and license agreement with Genentech secures the earliest licensed U.S. launch in the third quarter of 2028. The regulatory approval therefore marks a portfolio and market-access milestone, while commercial availability remains a later step.
Business Standard reported that the Genentech arrangement provides the earliest licensed U.S. launch window. The report also described the approval as Biocon's fifth U.S. oncology biosimilar milestone.
Oncology portfolio broadens
Pebrilzo joins Biocon's U.S. oncology portfolio of Ogivri, Jobevne, Fulphila and Aukelso. The company said its broader pipeline includes proposed biosimilars targeting trastuzumab and hyaluronidase, nivolumab and pembrolizumab. Investors will focus on launch preparation, market access and the timing of commercial sales as the 2028 window approaches.
Global biopharmaceutical platform
Biocon develops and manufactures biosimilars, generics, novel biologics and research services for patients in more than 120 countries. Its key therapy areas include diabetes, oncology, obesity, cardiovascular disease, immunology, ophthalmology and bone health, with headquarters in Bengaluru, India. Biocon operates in the same Indian pharmaceutical field as Glenmark Pharmaceuticals and Mankind Pharma; recent industry coverage linked those companies to separate oncology products and licensing activity.
Biocon company facts
- Company: Biocon Limited
- ISIN: INE376G01013
- Trading symbols: BSE 532523; NSE BIOCON
- Headquarters: Bengaluru, India
- Business: Biosimilars, generics, novel biologics and research services
- Global reach: More than 120 countries
India's broader equity backdrop is tracked through the BSE Sensex.
More news and analyses on Biocon stock.
